Navigation Links
The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
Date:5/3/2012

NEW YORK, NY, May 3, 2012 The Ludwig Institute for Cancer Research (LICR) announced today the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a novel pre-clinical pipeline of immunomodulators to stimulate the immune system's ability to attack cancer. Founded by LICR with the de Duve Institute at the Universit catholique de Louvain (UCL), iTeos is led by a team experienced in tumor immunology, immunotherapy, drug discovery, business development and entrepreneurship. iTeos is the ninth new company formed based on innovative cancer research discoveries licensed from LICR.

The field of cancer immunotherapy has come to the fore in the last two years with the approval of drugs and vaccines that harness the power of the immune system to treat cancer patients more safely, efficiently and effectively. However, therapeutic uses of these treatments can be limited as the tumors often develop mechanisms that enable them to escape the immune system. iTeos brings together world-class expertise in tumor immunology and immunotherapy, with a focus on developing small molecule immunomodulators to counteract cancer immunosuppression.

"Immunotherapy boosting the body's natural immune system to fight cancerous tumors is the next frontier in life-extending cancer treatment," said Benot Van den Eynde, M.D., Ph.D., Brussels Branch Director at LICR, UCL Professor and co-founder of iTeos. "Effective immunotherapy treatments enable the body's immune system to 're-engage' in destroying tumor cells, thereby potentially creating better patient outcomes with fewer side effects when compared to conventional cancer treatments."

"iTeos' mission is to translate pioneering scientific discovery into meaningful treatments for people living with cancer," said iTeos co-founder and CEO Michel Detheux, Ph.D. "We now know that combination treatments are likely to be more effective than single therapies in controlling and eventually eliminating cancer. iTeos will pursue this approach by combining existing vaccines with new immunodulatory compounds based on research that has just emerged from the Ludwig Institute."

iTeos' initial goals are to reach a proof of concept in humans by completing a Phase I/IIa study for the first compound program and to submit an Investigational New Drug application for a second candidate in four years.

Ludwig and UCL scientists, led by Dr. Van den Eynde, recently made the breakthrough discovery of the potential role of TDO in immunotherapy. TDO is a critical enzyme that is produced by a significant number of human tumors. In research published in the 30 January 2012 issue of Proceedings of the National Academy of Sciences, Dr. Van den Eynde's team showed that blocking TDO with a novel inhibitor promotes tumor rejection in mice. This team was also responsible for recognizing the role that a similar enzyme, IDO, plays in tumor growth. TDO and IDO inhibitors are now in preclinical development at iTeos.

"Preclinical studies suggest that TDO inhibition may be beneficial in treating bladder, liver and melanoma skin cancers. Suppressing IDO may help to positively impact ovarian, prostate, pancreatic and colorectal cancer treatment among others," said Dr. Detheux. "iTeos' focus is to bring these and other truly novel compounds to become part of the standard of care for cancer treatment."

"LICR has the expertise to conduct and administer its own early phase clinical trials as part of its technology development process," said Jonathan Skipper, Ph.D., Executive Director of Technology Development at LICR. "Spin-off companies, such as iTeos, have access to this infrastructure so that candidate therapeutics can be further tested. This allows LICR to continue to have input into the development of its discoveries and, more importantly, ensure promising new therapies will eventually reach patients."

Strong third-party endorsement is behind iTeos, including early funding by the Belgian Walloon Government. In fact, the creation of the spin-off was made possible by the grant from a Walloon FIRST spin-off mandate. Then, in December 2011, the Walloon Government awarded iTeos a research grant for $8M (6M). This support builds upon the progress of an earlier government program, the Biowin Pole of "Plan Marshall," aimed at the development of small molecule inhibitors.


'/>"/>
Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related medicine news :

1. Professor Cesare Montecucco to receive the 2011 Paul Ehrlich and Ludwig Darmstaedter Prize
2. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
3. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
4. National institute launched to help businesses grow with Asian consumers
5. Regenstrief Institute investigator recognized as a Top New Geriatrics Investigator
6. A.J. Drexel Autism Institute receives $1.5 million from the Charles and Barbara Close Foundation
7. American College of Cardiology honors 2 Cedars-Sinai Heart Institute physicians
8. Ragon Institute study finds HIV-specific CD4 cells that control viral levels
9. UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver
10. Professor from Karolinska Institutet now international educator
11. University Hospitals receives $5 million gift for Eye Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... After graduating from Cornell, author Joshua Alexander ... hospitals, on medication, living on Social Security disability and staying in a group home. ... Beat It!” (published by Balboa Press), Alexander shares how he was finally able to ...
(Date:5/24/2016)... Colorado (PRWEB) , ... May 24, 2016 , ... ... architecture firm, announces the grand opening of ‘El Centro del Quinto Sol Wheel ... of the Pueblo ‘east side’ community to offer something special for this often ...
(Date:5/24/2016)... ... 24, 2016 , ... NutraPre today announced the nationwide release ... to prevent morning sickness and promote overall heath. Engineered with advanced nanotechnology, this ... of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO Eddie Cameron ...
(Date:5/23/2016)... ... 23, 2016 , ... According to an article published May 12th on the Medical ... health and hygiene. The article points out that, as long as patients are brushing as ... worn and frayed. Of course, these worn-out bristles won’t clean teeth and gum tissue as ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical ... representatives from the Japan PMDA, US FDA, industry and academia at the ... help format data from clinical trials so that it can be shared and ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... AVIV, Israel , May 19, 2016 ... or the "Company"), an emerging global ophthalmic company focused ... product candidates which address ophthalmic conditions, announced today that ... Italy ) for the manufacturing, distribution, ... product for the treatment of dry eye syndrome (DES) ...
(Date:5/19/2016)... At the 18 th International Leksell Gamma ... , (May 15-19), Elekta announced that Leksell Gamma ... been used in the treatment of more than one ... functional disorders. Today, Gamma Knife surgery is ... hundreds of leading hospitals and clinics around the world. ...
(Date:5/19/2016)... -- The equities market is never short of ... is without doubt the Healthcare space. ActiveWallSt.com has uncovered four ... Alkermes PLC (NASDAQ: ALKS ), AMAG Pharmaceuticals Inc. ... IDXX ), and Atossa Genetics Inc. (NASDAQ: ... http://www.activewallst.com/ On Wednesday, Alkermes PLC,s ...
Breaking Medicine Technology: